Lisata Therapeutics logo
Lisata Therapeutics
LSTA | NASDAQ
Chart Builder DCF Calculator
$1.09
-$0.12 (-9.92%)
At close: Nov 16, 2026, 4:00 PM ET
$1.10
+$0.01 (+0.94%)
After-hours: Nov 16, 2026, 5:56 PM ET

Lisata Therapeutics Company Profile

Company profile explained

Company Profile

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.

Key Executives

Name Position
David J. Mazzo Chief Executive Officer & Director
James Nisco SVP of Finance and Treasury & Chief Accounting Officer
Joshua Lehrer-Graiwer FACC President & COO
Tariq Imam Head of Human Resources, Senior VP of Business Development & Operations and General Counsel

Latest SEC Filings

Date Type Title
Oct 19, 2026 ARS Filing
Oct 19, 2026 DEF 14A Filing
Oct 15, 2026 3 Filing
Oct 14, 2026 8-K Current Report
Oct 07, 2026 PRE 14A Filing
Oct 02, 2026 D Filing
Sep 28, 2026 3 Filing
Sep 28, 2026 3 Filing
Sep 17, 2026 8-K Current Report
Aug 26, 2026 SC 13G Statement of acquisition of beneficial ownership b...
View All SEC Filings ➞
Lisata Therapeutics
Lisata Therapeutics logo
Country United States
IPO Date Mar 1, 1999
Industry Biotechnology
Sector Healthcare
Employees 21
CEO David J. Mazzo

Contact Details

110 Allen Road Basking Ridge, New Jersey 07920 United States

Stock Details

Ticker Symbol LSTA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000320017
CUSIP Number 128058302
ISIN Number US1280583022
SIC Code 8090

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.